• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

26
24
19
18
13

COUNTRY

13
6
6
6

CATEGORIES

  • 77
  • 13
  • 12
  • 8
  • 8
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

78
96
103
123

PUBLISHED

4
4
10
123

PRODUCT TYPE

111
8
2
1
1

Search "Outcome Measures in Alzheimer's Disease" returned 123 results.

Alzheimer'S Disease: Pharmacuetical Drugs Vs. Medicinal Plants - Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts

The objective of this report is to provide a detailed analysis of Alzheimer’s disease (AD) and the pharmaceutical drugs and medicinal plants used to treat and prevent it. It also provides an overview...

July 2015
FROM

Alzheimer's Disease - Pipeline Review, H2 2014

Alzheimer's Disease - Pipeline Review, H2 2014 Summary This, ‘Alzheimer's Disease - Pipeline Review, H2 2014’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline. This report...

October 2014
FROM

Alzheimer's Disease - Pipeline Review, H1 2014

Alzheimer's Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2014’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline. This...

February 2014
FROM

Alzheimer's Disease - Pipeline Review, H1 2015

Alzheimer's Disease - Pipeline Review, H1 2015 Summary This, ‘Alzheimer's Disease - Pipeline Review, H1 2015’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline. This report...

January 2015
FROM

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely...

November 2011
FROM

Alzheimer's Disease - Pipeline Review, H2 2013

'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Alzheimer's Disease,...

August 2013
FROM

Alzheimer's Disease – Pipeline Review, H1 2013

Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

February 2013
FROM

Alzheimer's Disease - Pipeline Review, H2 2012

Alzheimer's Disease – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H2 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline....

August 2012
FROM

Targacept’s TC-5619 - The prospects for this fully-owned alpha-7 neuronal nicotinic receptor agonist

Earlier this year, Targacept reported that its phase II proof of concept study of TC-5619 in cognitive dysfunction in schizophrenia (CDS) met the pre-specified primary endpoint, while the trial in ADHD...

May 2011
FROM

Global Clinical Trials for Alzheimer's Disease

Global Clinical Trials for Alzheimer's Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important...

November 2013
Neuroprotection - Drugs, Markets and Companies Neuroprotection - Drugs, Markets and Companies - Product Thumbnail Image

Neuroprotection - Drugs, Markets and Companies

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many...

August 2015
FROM

Alzheimer's Disease - Pipeline Review, H1 2012

Alzheimer's Disease – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H1 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline....

February 2012
FROM

Alzheimer's Disease - Pipeline Review, Q1 2011

Alzheimer's Disease - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, Q1 2011', provides an overview of the Alzheimer's Disease therapeutic pipeline....

February 2011
FROM

Alzheimer's Disease - Pipeline Review, Q4 2010

Alzheimer's Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Alzheimer's Disease Pipeline Review, Q4 2010”, provides an overview of the Alzheimer's Disease therapeutic pipeline....

December 2010
FROM
Biomarkers - Technologies, Markets and Companies Biomarkers - Technologies, Markets and Companies - Product Thumbnail Image

Biomarkers - Technologies, Markets and Companies

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological...

August 2015
FROM

Alzheimer's Disease - Pipeline Review, H2 2011

Alzheimer's Disease - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H2 2011', provides an overview of the Alzheimer's Disease therapeutic pipeline....

September 2011
FROM

Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes

GBI Research’s new report, “Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes” provides information and analysis on the...

November 2012
FROM

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care...

January 2013
FROM

Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’ provides insights into major drug failures during 2005–2010 The 20 drugs...

July 2011
FROM
Molecular Diagnostics - Technologies, Markets and Companies Molecular Diagnostics - Technologies, Markets and Companies - Product Thumbnail Image

Molecular Diagnostics - Technologies, Markets and Companies

This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological...

August 2015
FROM
Loading Indicator

Our Clients

Glanbia Plc. Unilever N.V. Microsoft Corporation Duke University A.T. Kearney PepsiCo Inc. Boston Consulting Group